BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:H. Lundbeck readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies H. Lundbeck's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06660394-8867@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bexicaserin: Phase 3 readout est. (NCT06660394)
DESCRIPTION:Bexicaserin\, phase 3\, Epilepsy.\nStudy: A Phase 3\, Placebo-C
 ontrolled Study to Investigate LP352 in Children and Adults With Dravet Sy
 ndrome (DS)\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bexicaserin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06660394
URL:https://assetmemo.bio/drug/bexicaserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04965675-10396@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT04965675)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study With
  Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine\nEstimated
  primary completion: 26 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04965675
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05897320-10396@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT05897320)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study of E
 ptinezumab in Pediatric Participants With Episodic Migraine\nEstimated pri
 mary completion: 6 July 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/eptinezumab-vyepti#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05897320
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05325645-666@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Brexpiprazole (Rexulti): Phase 3 readout est. (NCT05325645)
DESCRIPTION:Brexpiprazole (Rexulti)\, phase 3\, Schizophrenia.\nStudy: Tria
 l of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Sch
 izophrenia\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05325645
URL:https://assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908226-8867@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:Bexicaserin: Phase 3 readout est. (NCT06908226)
DESCRIPTION:Bexicaserin\, phase 3\, Epilepsy.\nStudy: A Study to Investigat
 e LP352 in Children and Adults With Developmental and Epileptic Encephalop
 athy (DEE)\nEstimated primary completion: 11 November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bexicaserin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06908226
URL:https://assetmemo.bio/drug/bexicaserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05164172-10396@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Eptinezumab (Vyepti): Phase 3 readout est. (NCT05164172)
DESCRIPTION:Eptinezumab (Vyepti)\, phase 3\, Migraine.\nStudy: A Study With
  Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or E
 pisodic Migraine\nEstimated primary completion: 30 April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05164172
URL:https://assetmemo.bio/drug/eptinezumab-vyepti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514858-1646@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20281003
DTEND;VALUE=DATE:20281004
SUMMARY:Lu AF28996: Phase 2 readout est. (NCT07514858)
DESCRIPTION:Lu AF28996\, phase 2\, Parkinson's Disease.\nStudy: A Trial Inv
 estigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fl
 uctuations\nEstimated primary completion: 3 October 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lu-af28996#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07514858
URL:https://assetmemo.bio/drug/lu-af28996#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204314-845@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Trintellix (Vortioxetine): Phase 3 readout est. (NCT07204314)
DESCRIPTION:Trintellix (Vortioxetine)\, phase 3\, Major Depressive Disorder
 .\nStudy: A Study of Vortioxetine in Japanese Pediatric Patients With Majo
 r Depressive Disorder\nEstimated primary completion: 30 September 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/vortioxetine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07204314
URL:https://assetmemo.bio/drug/vortioxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
